Progenerics Pharma Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 6.83 Cr
as on 17-12-2024
- Company Age 9 Year, 21 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 Cr
as on 17-12-2024
- Revenue -85.68%
(FY 2023)
- Profit -532.89%
(FY 2023)
- Ebitda -261.84%
(FY 2023)
- Net Worth -41.54%
(FY 2023)
- Total Assets -17.22%
(FY 2023)
About Progenerics Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 6.83 Cr.
The company has closed loans amounting to ₹5.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sreekanth Joginapally and Rajashekar Mesineni serve as directors at the Company.
- CIN/LLPIN
U24233TG2015PTC102075
- Company No.
102075
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Dec 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Progenerics Pharma Private Limited offer?
Progenerics Pharma Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services, Business Planning and Management, Business Consultant.
Who are the key members and board of directors at Progenerics Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sreekanth Joginapally  | Director | 05-Dec-2015 | Current |
| Rajashekar Mesineni | Director | 05-Dec-2015 | Current |
Financial Performance of Progenerics Pharma.
Progenerics Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 85.68% decrease. The company also saw a substantial fall in profitability, with a 532.89% decrease in profit. The company's net worth observed a substantial decline by a decrease of 41.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Progenerics Pharma?
In 2023, Progenerics Pharma had a promoter holding of 59.72% and a public holding of 40.28%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Aug 2016 | ₹5.00 Cr | Satisfied |
How Many Employees Work at Progenerics Pharma?
Progenerics Pharma has a workforce of 27 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Progenerics Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Progenerics Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
